A Look at where Biopharma Bucks are Going in 2022

Although treating patients is the top priority of the biopharma industry, there’s no doubt that money is the driver. And that can range from what patients and insurers pay, to funding from government entities, and what investors, both private and public are backing with their money. This is a broad look at the current state of biopharma bucks.